Lung cancer and its association with chronic obstructive pulmonary disease: Update on nexus of epigenetics

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 4, 2011, Pages 279-285

  Sundar, Isaac K ^a   Mullapudi, Nandita ^b   Yao, Hongwei ^a   Spivack, Simon D ^b   Rahman, Irfan ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

chromatin; chronic obstructive pulmonary disease; epigenetics; histones; lung cancer; methylation

Indexed keywords

ANTIOXIDANT; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; GROWTH FACTOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; HISTONE DEMETHYLASE; HISTONE H3; HISTONE H4; HISTONE METHYLTRANSFERASE; KETONE; METHYL CPG BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINE DERIVED NITROSAMINE KETONE; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN P16; PROTEIN P300; PROTEIN P53; SIRTUIN 1; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DEACETYLATION; DEMETHYLATION; DISEASE ASSOCIATION; DNA DETERMINATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MACROPHAGE; OXIDATIVE STRESS; PNEUMONIA; REVIEW; SENESCENCE; TIGHT JUNCTION; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-CYTOSINE METHYLASES; EPIGENOMICS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONE DEMETHYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LUNG NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 79958820786     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283477533     Document Type: Review

References (75)

1. Mannino DM, Aguayo SM, Petty TL, et al. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163:1475-1480. (Pubitemid 36758921)
2. Yao H, Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol 2009; 9:375-383.
3. Berger SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002; 12:142-148. (Pubitemid 34219485)
4. Ruthenburg AJ, Li H, Patel DJ, et al. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 2007; 8:983-994. (Pubitemid 350174643)
5. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007; 447:407-412. (Pubitemid 46816746)
6. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009; 41:87-95.
7. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007; 8:253-262. (Pubitemid 46439287)
8. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4:707-717. (Pubitemid 39215069)
9. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-2054. (Pubitemid 37448928)
10. Liu F, Killian JK, Yang M, et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 2010; 29:3650-3664. This study provides evidence that cigarette smoke mediates 'cancer-associated' epigenomic alterations in cultured human lung epithelial cells. Thus, in-vitro studies may have significant impact on delineating the early epigenetic mechanisms regulating gene expression during pulmonary carcinogenesis.
11. Lin RK, Wu CY, Chang JW, et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 2010; 70:5807-5817.
12. Lin RK, Hsieh YS, Lin P, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 2010;120:521-532. This study provides cell, animal, and clinical evidence that NNK induces DNA methyltransferase 1 via AKT/GSK3β/βTrCP/hnRNP-U signaling pathway to demonstrate the mechanism in smoking-mediated lung cancer.
13. Tsou JA, Hagen JA, Carpenter CL, et al. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002; 21:5450-5461. (Pubitemid 34983481)
14. Brabender J, Usadel H, Danenberg KD, et al. Adenomatous polyposis coli gene promoter hypermethylation in nonsmall cell lung cancer is associated with survival. Oncogene 2001; 20:3528-3532. (Pubitemid 32619405)
15. Kim DH, Nelson HH, Wiencke JK, et al. Promoter methylation of DAP-kinase: association with advanced stage in nonsmall cell lung cancer. Oncogene 2001; 20:1765-1770. (Pubitemid 32368022)
16. Sanchez-Cespedes M, Decker PA, Doffek KM, et al. Increased loss of chromosome 9p21 but not p16 inactivation in primary nonsmall cell lung cancer from smokers. Cancer Res 2001; 61:2092-2096. (Pubitemid 32692032)
17. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in nonsmall cell lung cancer. Cancer Res 2001; 61:3419-3424.
18. Kersting M, Friedl C, Kraus A, et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000; 18:3221-3229.
19. Hou M, Morishita Y, Iljima T, et al. DNA methylation and expression of p16(INK4A) gene in pulmonary adenocarcinoma and anthracosis in background lung. Int J Cancer 1999; 84:609-613.
20. Eguchi K, Kanai Y, Kobayashi K, et al. DNA hypermethylation at the D17S5 locus in nonsmall cell lung cancers: its association with smoking history. Cancer Res 1997; 57:4913-4915. (Pubitemid 27469002)
21. Beleford D, Liu Z, Rattan R, et al. Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Clin Cancer Res 2010; 16:398-409.
22. Takeshita M, Koga T, Takayama K, et al. CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung, and the diminished expression significantly harms outcomes. Int J Cancer 2008; 123:1623-1630.
23. Suzuki M, Wada H, Yoshino M, et al. Molecular characterization of chronic obstructive pulmonary disease-related nonsmall cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol 2010; 17:878-888. This study identifies two genes (IL-12Rb2 and Wif-1) from a panel of 12 for which promoter hypermethylation was significantly associated with COPD when compared to non-COPD study participants. It is one of the few studies that examine methylation events specifically associated with COPD in NSCLC patients.
24. Wang R, An J, Ji F, et al. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008; 373:151-154.
25. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006; 3:e486.
26. Dammann R, Strunnikova M, Schagdarsurengin U, et al. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer 2005; 41:1223-1236. (Pubitemid 40725582)
27. Luxen S, Belinsky SA, Knaus UG. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res 2008; 68:1037-1045. (Pubitemid 351272221)
28. Harden SV, Tokumaru Y, Westra WH, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003; 9:1370-1375. (Pubitemid 36418388)
29. Shivapurkar N, Stastny V, Okumura N, et al. Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res 2008; 68:7448-7456.
30. Zelko IN, Mueller MR, Folz RJ. CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression. Free Radic Biol Med 2010; 48:895-904.
31. Sood A, Petersen H, Blanchette CM, et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. Am J Respir Crit Care Med 2010; 182:1098-1104. This study demonstrates a significant association between smokers with CpG methylation at the p16 and GATA4 genes and lowered lung function when compared to smokers without these epigenetic changes. It is one of the few studies that examine methylation events specifically associated with COPD particularly in response to wood smoke.
32. Marwick JA, Kirkham PA, Stevenson CS, et al. Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol 2004; 31:633-642. (Pubitemid 39587493)
33. Rahman I. Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. J Biochem Mol Biol 2003; 36:95-109. (Pubitemid 36836261)
34. Szulakowski P, Crowther AJ, Jimenez LA, et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:41-50. (Pubitemid 43955243)
35. Yang SR, Valvo S, Yao H, et al. IKK alpha causes chromatin modification on pro-inflammatory genes by cigarette smoke in mouse lung. Am J Respir Cell Mol Biol 2008; 38:689-698. (Pubitemid 351841570)
36. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352:1967-1976. (Pubitemid 40638367)
37. Thomson S, Clayton AL, Hazzalin CA, et al. The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J 1999; 18:4779-4793. (Pubitemid 29415531)
38. Bedford DC, Kasper LH, Fukuyama T, et al. Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases. Epigenetics 2010; 5:9-15.
39. Chen L, Fischle W, Verdin E, et al. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001; 293:1653-1657. (Pubitemid 32807844)
40. Yao H, Hwang JW, Moscat J, et al. Protein kinase C zeta mediates cigarette smoke/aldehyde- and lipopolysaccharide-induced lung inflammation and histone modifications. J Biol Chem 2010; 285:5405-5416. This study demonstrates a novel role of PKCz in cigarette smoke/aldehyde-mediated and LPS-mediated inflammatory response and chromatin modifications in the lungs. These findings also provide new insights on the molecular mechanisms underlying the pathogenesis of chronic lung diseases.
41. Gloire G, Horion J, El Mjiyad N, et al. Promoter-dependent effect of IKKalpha on NF-kappaB/p65 DNA binding. J Biol Chem 2007; 282:21308-21318. (Pubitemid 47099906)
42. Kishimoto M, Kohno T, Okudela K, et al. Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res 2005; 11:512-519. (Pubitemid 40116874)
43. Horwitz GA, Zhang K, McBrian MA, et al. Adenovirus small e1a alters global patterns of histone modification. Science 2008; 321:1084-1085.
44. Dekker FJ, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug Discov Today 2009; 14:942-948.
45. Tjeertes JV, Miller KM, Jackson SP. Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J 2009; 28:1878-1889.
46. Adenuga D, Yao H, March TH, et al. Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am J Respir Cell Mol Biol 2009; 40:464-473.
47. Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 2006; 291:L46-L57.
48. Nakamaru Y, Vuppusetty C, Wada H, et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 2009; 23:2810-2819.
49. Rajendrasozhan S, Yang SR, Kinnula VL, et al. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:861-870. (Pubitemid 351600664)
50. Adenuga D, Caito S, Yao H, et al. Nrf2 deficiency influences susceptibility to steroid resistance via HDAC2 reduction. Biochem Biophys Res Commun 2010; 403:452-456. Important finding showing that loss of HDAC2 is a critical factor in inhaled toxicant-mediated lung inflammation especially in regulating the anti-inflammatory effects of glucocorticoids in mouse lungs. This may have implications for devising better therapies for steroid insensitive patients to treat chronic lung diseases.
51. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006; 203:7-13. (Pubitemid 43139638)
52. Meja KK, Rajendrasozhan S, Adenuga D, et al. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol 2008; 39:312-323.
53. Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004; 112:26-32. (Pubitemid 39249488)
54. Peters AH, O'Carroll D, Scherthan H, et al. Loss of the Suv39H histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001; 107:323-337. (Pubitemid 33049976)
55. Litt M, Qiu Y, Huang S. Histone arginine methylations: their roles in chromatin dynamics and transcriptional regulation. Biosci Rep 2009; 29:131-141.
56. Spannhoff A, Heinke R, Bauer I, et al. Target-based approach to inhibitors of histone arginine methyltransferases. J Med Chem 2007; 50:2319-2325. (Pubitemid 46799244)
57. Yang J, Jubb AM, Pike L, et al. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res 2010; 70:6456-6466. This study highlights that histone demethylase JMJD2B is regulated by both estrogen receptor a and hypoxia-inducible factor 1a, and drives breast cancer cell proliferation in normoxia and hypoxia. Thus, targeting histone demethylase in hypoxic condition which occurs in lung cancer may be crucial.
58. Krieg AJ, Rankin EB, Chan D, et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol 2010; 30:344-353. This study demonstrates that loss of JMJD1A is sufficient to reduce tumor growth in vivo, and histone demethylation plays a significant role in modulating growth within the tumor microenvironment.
59. Zhou X, Sun H, Chen H, et al. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase. Cancer Res 2010; 70:4214-4221. This study highlights that hyperoxia leads to induction of global as well as gene-specific H3K4me3 in normal human bronchial epithelial cells and human lung carcinoma cells, which plays a vital role in hyperoxia-induced altered gene expression and tumor progression.
60. Hayami S, Yoshimatsu M, Veerakumarasivam A, et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer 2010; 9:59.
61. Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200:689-695. (Pubitemid 39258317)
62. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 2002; 99:8921-8926. (Pubitemid 34693659)
63. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1:19-25. (Pubitemid 46776612)
64. Shan B, Yao TP, Nguyen HT, et al. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem 2008; 283:21065-21073.
65. Haberland M, Johnson A, Mokalled MH, et al. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A 2009; 106:7751-7755.
66. Miller KM, Tjeertes JV, Coates J, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 2010; 17:1144-1151. This study describes the importance of HDAC1 and HDAC2 in DNA-damage response by promoting double-strand break repair. Findings from this study provides better insights on the radio-sensitizing effects of HDAC inhibitors against cancer therapy.
67. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705. (Pubitemid 46273577)
68. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37:391-400.
69. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009; 8:1409-1420.
70. Tessema M, Klinge DM, Yingling CM, et al. Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 2010; 29:5159-5170.
71. Liu H, Zhou Y, Boggs SE, et al. Cigarette smoke induces demethylation of prometastatic oncogene synuclein-gamma in lung cancer cells by down-regulation of DNMT3B. Oncogene 2007; 26:5900-5910.
72. Tian X, Fang J. Current perspectives on histone demethylases. Acta Biochim Biophys Sin (Shanghai) 2007; 39:81-88.
73. Lim S, Janzer A, Becker A, et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010; 31:512-520.
74. Grant S. Targeting histone demethylases in cancer therapy. Clin Cancer Res 2009; 15:7111-7113.
75. Schwartz DA. Epigenetics and environmental lung disease. Proc Am Thorac Soc 2010; 7:123-125.